Common and different roles of IL-4 and IL-13 in skin allergy and clinical implications. Issue 4 (August 2019)

• Record Type: Journal Article
• Authors: Roesner, Lennart M.; Zeitvogel, Jana; Heratizadeh, Annice
• Is Part Of: Current opinion in allergy and clinical immunology. Volume 19:Issue 4(2019:Aug.)
• Publication Date: 2019-08
• Subjects: allergy -- atopic dermatitis -- baricitinib -- biological -- dupilumab -- lebrikizumab -- MEDI-9314 -- Pf-04965842 -- skin -- tofacitinib -- tralokinumab -- upadacitinib; Allergy -- Periodicals; Clinical immunology -- Periodicals; Hypersensitivity; Immunity; Immune System Diseases; Allergy and Immunology; 616.079
• DOI: 10.1097/ACI.0000000000000553
• Languages: English
• ISSNs: 1528-4050

Abstract

Abstract : Purpose of review: This review summarizes the mode of action of IL-4 and IL-13 in skin allergy, upcoming therapeutics and depicts key outcomes of the latest clinical trials. Recent findings: Atopic dermatitis is considered to be one of the most common inflammatory skin disease in industrialized countries. Accompanied by strong pruritus, atopic dermatitis has a significant impact on quality of life in severely affected individuals. Aside from unspecific immunosuppressant medications, therapeutics targeting the key cytokines IL-4 and IL-13 and their downstream mediators are under development or have been approved just recently with outstanding potential. Summary: The recent development of several biologics and small compounds has the potential to revolutionize the treatment of atopic dermatitis, and applying this set of state-of-the-art drugs will provide a unique chance to gain insights into this skin disorder, patient subgroups, and key inflammatory mediators.